Anaptys Announces Participation in September Investor Conferences

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics [2] - The company is developing immune cell modulators for autoimmune and inflammatory diseases, including two checkpoint agonists: ANB032 for atopic dermatitis and rosnilimab for rheumatoid arthritis and ulcerative colitis [2] - AnaptysBio has additional candidates in its portfolio, such as ANB033, an anti-CD122 antagonist antibody in Phase 1 trial, and ANB101, a BDCA2 modulator antibody in preclinical development [2] - The company has developed two cytokine antagonists for out-licensing: imsidolimab for generalized pustular psoriasis and etokimab, which is Phase 2/3 ready [2] - AnaptysBio has also discovered multiple therapeutic antibodies licensed to GSK for immuno-oncology, including Jemperli and cobolimab [2] Upcoming Investor Conferences - AnaptysBio's CEO Daniel Faga and senior management will participate in several investor conferences [1] - The 2024 Wells Fargo Healthcare Conference will take place on September 5, 2024, featuring a fireside chat and one-on-one meetings [1] - The Stifel 2024 Virtual Immunology and Inflammation Summit is scheduled for September 17, 2024, with a fireside chat format [1] - The 2024 Cantor Fitzgerald Global Healthcare Conference will occur on September 18, 2024, also including a fireside chat and one-on-one meetings [1] - Live webcasts of the fireside chats will be available on AnaptysBio's investor website, with replays accessible for at least 30 days [1]